Variant Creutzfeldt-Jakob Disease Impact on U.S. Military Service Members Lt. Col. David Lincoln Deputy Director Armed Services Blood Program Office Unclassified.

Slides:



Advertisements
Similar presentations
Creutzfeldt-Jakob Disease Classic CJD occurs worldwide at 1-2 cases per million population per year In people over 50, the annual rate is about 3.4 per.
Advertisements

BLACK GOLD.
FDA Workshop “Data and Data Needs to Advance Risk Assessment for Emerging Infectious Diseases for Blood and Blood Products” November 29, 2011, Gaithersburg.
Bovine Spongiform Encephalopathy (BSE) in Canada Pedro Piccardo, MD Division of Emerging and Transfusion-Transmitted Diseases Office of Blood Research.
Draft Guidance for Industry: Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob.
1 Donor Deferral / Ineligibility for Time Spent in Saudi Arabia to Reduce Risk of vCJD Transmitted by Blood and Blood Products and by Human Cells, Tissues.
Current Fiscal Year Soft EAOS Metrics
SS7H2. Persian Gulf War began on August 2, It was a conflict between Iraq and 32 other nations including USA, Britain, Egypt, France, and Saudi.
Reason for Blood Donor Deferral for Exposure to Leishmaniasis Presented by deployment illness advocate Venus-Val Hammack 12/11/03 HQ: Mass State House,
DESERT SHIELD and DESERT STORM
BELLWORK How did Saddam justify his invasion of Kuwait?
BSE outbreaks in the United States and Canada and the Impact on Trade Hyun J. Jin Won W. Koo Center for Agricultural Policy and Trade Studies North Dakota.
FDA Transmissible Spongiform Encephalopathies Advisory Committee 23 rd Meeting 01 August 2011 Gaithersburg MD Donor Deferral/Ineligibility for Time Spent.
ADMINISTRATIVE  Mid-Term Test Next Week 1. 2 Samples of Behavior  List key lessons learned from Operation PROVIDE COMFORT/NORTHERN WATCH, Operation.
Presumptive Transfusion Transmissions of vCJD: Introduction to Consideration of Current FDA-recommended Safeguards FDA TSE Advisory Committee 16 th Meeting.
3.4. The Gulf War Iraqi Invasion of Kuwait (1 Aug. 1990)
Workshop Summary FDA Workshop on Testing for malarial Infections in Blood Donors Sanjai Kumar, Ph.D. Center for Biologics Evaluation and Research Food.
Transmissible Spongiform Encephalopathies Advisory Committee 23 rd Meeting Gaithersburg, MD – August 1, 2011 CJD and vCJD Donor Policies: Blood and Blood.
Canadian and U.S. BSE Risk Steven Anderson, Ph.D, MPP Office of Biostatistics & Epidemiology Center for Biologics Evaluation & Research U.S. Food & Drug.
The Persian Gulf War & U.S. Involvement Information from Fact Monster Pictures from Wikipedia.
21 August 2015 Samreen Ijaz Virus Reference Department Health Protection Agency Indigenous HEV infection in the UK: a hazard for blood donation?
Prion Diseases Microbes and Society Fall What is a Prion? Prion- small proteinaceous infectious particles which resist inactivation by procedures.
FDA Blood Products Advisory Committee Meeting 03 August 2011 Gaithersburg MD Summary of Transmissible Spongiform Advisory Committee Meeting 01 August 2011.
 Caused by parasite › Transmitted by mosquito › Once injected into the human, the parasite grows and multiples first in the liver and then the red blood.
Persian Gulf War #1 Operation Desert Shield and Desert Storm
Persian Gulf War August 1990-February 1991 Opponent: Iraq (Saddam Hussein) Allies: 22 nation coalition (16 involved in combat) President: George H.W. Bush.
Airpower Through The Post Cold War. Overview  Background to the Conflict  Iraqi threats  The Plan of Attack  Concept of Operations  Five Strategic.
Development of FDA Recommendations for deferral of donors based on risk of BSE exposure Alan E. Williams, Ph.D. Director, Division of Blood Applications.
ROA Department of Minnesota Congressional Breakfast LtCol Doug Kveene, President LTC Karl Rasmussen, Director, Legislative Affairs.
Program Overview Marty Ricker Recruiter Supervisor.
Challenges in evaluating and changing donor criteria Dr. Mindy Goldman Transfusion Medicine Residents April 30, 2008.
Building Healthcare for the Iraqi Military & Police Presentation to the 2006 Tri-Service Symposium 14 July 2006.
DoD Region 4 Pollution Prevention Project Task 8: Database Development and EMS Integration Phil Barnes University of South Carolina.
Current Military Expenditures Top 20 United States$305.4 Billion Russia $55.0 Japan $41.1 China $37.5 United Kingdom $34.6 France $29.5 Germany $24.7 Saudi.
Creating and Seizing Opportunities to Serve the Military Case Study: Air Force Clinical Training Project David Litts Associate Director, Suicide Prevention.
1 U.S. vCJD Donor Screening: Human Cells, Tissues, and Cellular and Tissue- Based Products (HCT/Ps) Melissa A Greenwald, MD CAPT, U.S. Public Health Service.
Why did the US oppose Iraq invading Kuwait?. Conflicts in the Middle East.
American Red Cross, vCJD Donor Deferral Criteria, and Blood Supply Peter L. Page, MD Senior Medical Officer Biomedical Headquarters TSEAC 06/27/02.
Armed Services Blood Program Program Overview Marty Ricker Recruiter Supervisor.
A Self Study Powerpoint
Airpower Through The Post Cold War
Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.
Presumed Consent Vs Informed Consent
RISK COMMUNICATION APPROACH TSEAC 15 December 2006 Mark Weinstein, Ph.D. FDA, Center for Biologics Evaluation and Research.
General Information OPEC Currency The 1973 Oil Crisis
UNCLASSIFIED 27 Jun 02 Armed Services Blood Program TSEAC Update – vCJD Deferrals RONNY G. ALFORD, Major, USAF, BSC Deputy Director, Armed Services Blood.
Modeling Risk of vCJD in US Donors – Residual Risk and Efficiency of Donor Deferral Alan E. Williams, Ph.D. Director, Division of Blood Applications Office.
Hong Yang, Ph.D. Office of Biostatistics and Epidemiology FDA-Center for Biologics Evaluation & Research Transmissible Spongiform Encephalopathies Advisory.
Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies;
BSE: World update FDA TSE Advisory Committee Gaithersburg, MD September 18, 2006 Lisa A. Ferguson, DVM Senior Staff Veterinarian USDA, APHIS, Veterinary.
Microbes and Diseases Chapter 02. CREUTZFELDT-JAKOB DISEASE Prion.
Preliminary Risk Assessment Model for U.S. Plasma Derivatives and vCJD Steven Anderson, PhD, MPP Office of Biostatistics & Epidemiology Center for Biologics.
Risk Assessment: Questions to the Committee 1.What estimate(s) should be used to reflect the prevalence of vCJD in the U.K.? Proposal: We propose using.
American Red Cross: Evolution of vCJD Donor Deferral Criteria and Blood Supply Peter L. Page, MD Senior Medical Officer Biomedical Headquarters TSEAC February.
Identification and Deferral of Tissue Donors for Possible BSE/vCJ-D Exposure: Estimating the Impact Alan E. Williams, Ph.D. Director, Division of Blood.
VCJD World situation and Updates RG Will National CJD Research and Surveillance Unit Edinburgh, UK TSEAC meeting 1 st August 2011.
Topic 1: FDA Draft Guidance “Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products” Dorothy.
Deferral of Blood and Plasma Donors for History of Transfusion in BSE Countries of Europe Alan E. Williams, Ph.D. Director, Division of Blood Applications.
David M. Asher, MD Division of Emerging & Transfusion-Transmitted Diseases Office of Blood Research & Review Center for Biologics Evaluation & Research.
Slide 1 "CJD Lookback Study" (Research Study to Assess the Risk of Blood Borne Transmission of CJD) American Red Cross Blood Services TSEAC October 14,
Canada and the United Nations Persian Gulf War ( ) Presented by Kohun, Riley and Justine.
FDA Risk Management Strategy for Potential Exposure to vCJD from Plasma Derivatives TSE Advisory Committee December 15, 2006 Dorothy Scott, M.D. OBRR/CBER.
FDA’s vCJD Risk Communication on US Plasma- Derived Factor VIII and UK Plasma-Derived Factor XI BPAC April 27, 2007 Mark Weinstein, Ph.D. FDA, Center for.
Bad Blood? An Investigation of the MSM Ban on Blood Donation Lauren Lacy Abstract In 1983, the Food and Drug Administration (FDA), responding to the AIDS.
How dangerous are Donor Travels?
Disclaimer This presentation is being provided solely for informational purposes. Mercantile Exchange Nepal Limited does not warrant the accuracy or completeness.
ANALYSIS OF THE DEPARTMENT OF DEFENCE BUDGET FOR 2015/16
Bovine Spongiform Encephalopathy Variant Creutzfeldt-Jakob disease
2017 FISCAL YEAR Economic Impact Analysis Nellis Air Force Base
The Government’s Role in Stabilizing Beef Supply when BSE Strikes
Presentation transcript:

Variant Creutzfeldt-Jakob Disease Impact on U.S. Military Service Members Lt. Col. David Lincoln Deputy Director Armed Services Blood Program Office Unclassified Slide 1

vCJD-DoD Current Deferral Policy  In residence or traveled to UK cumulative ≥3 mo( )  DoD & affiliated personnel in residence or traveled to BSE risk countries (Europe) cumulative ≥6 mo ( )*  DoD affiliated personnel in residence or traveled to BSE risk countries (Europe) cumulative ≥5 yrs (after 1996)  Other personnel in residence or traveled to BSE risk countries (Europe) ≥5 yrs or more (1980-present)  Transfusion blood/blood product in UK or France (1980-present)  Received bovine insulin prepared in the UK since 1980 *No distinction for Northern Europe vs. South of the Alps Unclassified Slide 2

Saudi Arabia Residency vCJD Deferral  New vCJD case in Canada  Believed to have contracted vCJD while living in Saudi Arabia  Two other patients from outside Canada also believed to have contracted vCJD while living in Saudi Arabia  Canadian Blood Services to follow Héma-Québec (2008) and implement an indefinite deferral for donors who spent >6 months (cumulative) in Saudi Arabia  DoD implementing same deferral effective Aug/Sep 2011 Unclassified Slide 3

Rationale Supporting Deferral  Between 1980 and 1996, Saudi Arabia imported beef from the U.K., which could have been exposed to BSE-- U.K. beef was likely available at DoD facilities  1990 DoD begins to discontinue purchase of UK beef  Interviews with DoD Veterinary Command consultants and personnel deployed to Saudi Arabia for Desert Shield/Desert Storm indicate:  U.K. beef consumption by U.S. military, civilians, and contractor personnel during that period  Estimated 10% proportion of UK beef to total beef consumed by US forces in Saudi Arabia during DS/DS force due to beef consumption on local economy. Contractors may be higher Unclassified Slide 4

Rationale supporting deferral  Not known with certainty if vCJD cases related to food consumption in Saudi Arabia, but a possible source of infection  It is possible that other bases within the Persian Gulf region may have acquired U.K beef during this time frame  May have been acquired indirectly by third party  Possible expansion of DoD deferral to include the entire Gulf Region under consideration Unclassified Slide 5

Deployments to Saudi Arabia 1980 – 2003  U.S. Military Training Mission (USMTM) Saudi Arabia ( )  Approximately 1,000 troops deployed annually  Operation Desert Shield/Storm (Aug 1990-Sept 1991)  Approximately 550,000 troops deployed  90% greater than 6 months  Operation Southern Watch ( )  U.S. combat troops and air crews enforce southern Iraqi “no-fly” zone  Approximately 5,000 troops deployed annually Unclassified Slide 6

Loss to Blood Supply from DoD Exposure  Estimated number of U.S. troops based in Saudi Arabia from = 590,000  Fact: DoD civilians, government civilians, contractors could add another 200,000  Assumption: 5% blood donor population 790,000 X 5% = 39,500 donors  However, approximately 30% of this population already deferred for vCJD risk based on European deferral or other conditions.  A large number of this population retired or left active duty service and may be donating to civilian blood collection facilities  Impact to Blood Supply appears to be minimal Unclassified Slide 7

LOOKBACKs  No recipient look backs based solely on new geographic risk deferrals will be performed by DoD Unclassified Slide 8